Reno-cerebrovascular disease: linking the nephron and neuron

References

• Weening JJ, Remuzzi G. Exciting times for renal medicine. Lancet375, 1227–1228 (2010).
   PubMed Web of Science ®Google Scholar
• Brosius FC, Hostetter TH, Kelepouris E et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease – a science advisory from the American Heart Association Kidney and Cardiovascular Disease Council; the councils on high blood pressure research, cardiovascular disease in the young, and epidemiology and prevention; and the quality of care and outcomes research interdisciplinary working group. Circulation114, 1083–1087 (2006).
   PubMed Web of Science ®Google Scholar
• Kirby T. Screening for chronic kidney disease shows promise. Lancet375, 1240–1241 (2010).
   PubMed Web of Science ®Google Scholar
• James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet375, 1296–1309 (2010).
   PubMed Web of Science ®Google Scholar
• Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation116, 85–97 (2007).
   PubMed Web of Science ®Google Scholar
• Monk RD, Bennett DA. Reno-cerebrovascular disease? The incognito kidney in cognition and stroke. Neurology67, 196–198 (2006).
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med.139, 137–147 (2003).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B. Impairment in glomerular filtration rate or glomerular filtration barrier and occurrence of stroke. Arch. Neurol.65, 934–938 (2008).
   PubMedGoogle Scholar
• Aguilar MI, O’Meara ES, Seliger S et al. Albuminuria and the risk of incident stroke and stroke types in older adults. Neurology75, 1343–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Impact of microalbuminuria on incident stroke: a meta-analysis. Stroke41, 2625–2631 (2010).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B. Microalbuminuria: risk factor and potential therapeutic target for stroke? J. Neurol. Sci.271, 21–28 (2008).
   PubMed Web of Science ®Google Scholar
• de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J. Am. Soc. Nephrol.17, 2100–2105 (2006).
   PubMed Web of Science ®Google Scholar
• Pucci L, Triscornia S, Lucchesi D et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin. Chem.53, 480–488 (2007).
   PubMed Web of Science ®Google Scholar
• Coll E, Botey A, Alvarez L et al. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am. J. Kidney Dis.36, 29–34 (2000).
   PubMed Web of Science ®Google Scholar
• Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am. J. Kidney Dis.37, 79–83 (2001).
   PubMed Web of Science ®Google Scholar
• Kurella M, Yaffe K, Shlipak MG, Wenger NK, Chertow GM. Chronic kidney disease and cognitive impairment in menopausal women. Am. J. Kidney Dis.45, 66–76 (2005).
   PubMed Web of Science ®Google Scholar
• Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study. J. Am. Soc. Nephrol.16, 2127–2133 (2005).
   PubMed Web of Science ®Google Scholar
• Khatri M, Wright CB, Nickolas TL et al. Chronic kidney disease is associated with white matter hyperintensity volume: the Northern Manhattan Study (NOMAS). Stroke38, 3121–3126 (2007).
   PubMed Web of Science ®Google Scholar
• Ikram MA, Vernooij MW, Hofman A, Niessen WJ, van der Lugt A, Breteler MM. Kidney function is related to cerebral small vessel disease. Stroke39, 55–61 (2008).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Liebeskind DS, Pineda S, Saver JL. Strong independent correlation of proteinuria with cerebral microbleeds in patients with stroke and transient ischemic attack. Arch. Neurol.67, 45–50 (2010).
   PubMedGoogle Scholar
• Price TR, Manolio TA, Kronmal RA et al. Silent brain infarction on magnetic resonance imaging and neurological abnormalities in community-dwelling older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Stroke28, 1158–1164 (1997).
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N. Engl. J. Med.348, 1215–1222 (2003).
   PubMed Web of Science ®Google Scholar
• Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology57, 1222–1229 (2001).
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Okada K, Koide H, Bokura H, Yamaguchi S. Subcortical silent brain infarction as a risk factor for clinical stroke. Stroke28, 1932–1939 (1997).
   PubMed Web of Science ®Google Scholar
• Vermeer SE, Den Heijer T, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke34, 392–396 (2003).
   PubMed Web of Science ®Google Scholar
• Koren-Morag N, Goldbourt U, Tanne D. Renal dysfunction and risk of ischemic stroke or TIA in patients with cardiovascular disease. Neurology67, 224–228 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng TY, Wen SF, Astor BC, Tao XG, Samet JM, Wen CP. Mortality risks for all causes and cardiovascular diseases and reduced GFR in a middle-aged working population in Taiwan. Am. J. Kidney Dis.52, 1051–1060 (2008).
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: a meta-analysis. BMJ341, c4249 (2010).
   PubMed Web of Science ®Google Scholar
• Ninomiya T, Perkovic V, Verdon C et al. Proteinuria and stroke: a meta-analysis of cohort studies. Am. J. Kidney Dis.53, 417–425 (2009).
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Chang KH, Ovbiagele B. Level of albuminuria and risk of stroke: systematic review and meta-analysis. Cerebrovasc. Dis.30, 464–469 (2010).
   PubMed Web of Science ®Google Scholar
• Menon V, Shlipak MG, Wang X et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann. Intern. Med.147, 19–27 (2007).
   PubMed Web of Science ®Google Scholar
• Lee M, Saver JL, Huang WH, Chow J, Chang KH, Ovbiagele B. Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ. Cardiovasc. Qual. Outcomes3(6), 675–683 (2010).
   PubMed Web of Science ®Google Scholar
• Slowik A, Turaj W, Iskra T, Strojny J, Szczudlik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: prevalence, clinical correlates, and prognostic significance. Cerebrovasc. Dis.14, 15–21 (2002).
   PubMed Web of Science ®Google Scholar
• Terao Y, Takada M, Tanabe T, Ando Y, Fukusaki M, Sumikawa K. Microalbuminuria is a prognostic predictor in aneurysmal subarachnoid hemorrhage. Intensive Care Med.33, 1000–1006 (2007).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B, Sanossian N, Liebeskind DS et al. Indices of kidney dysfunction and discharge outcomes in hospitalized stroke patients without known renal disease. Cerebrovasc. Dis.28, 582–588 (2009).
   PubMed Web of Science ®Google Scholar
• Ovbiagele B. Chronic kidney disease and risk of death during hospitalization for stroke. J. Neurol. Sci.301(1-2), 46–50 (2011).
   PubMed Web of Science ®Google Scholar
• Ani C, Ovbiagele B. Relation of baseline presence and severity of renal disease to long-term mortality in persons with known stroke. J. Neurol. Sci.288, 123–128 (2010).
   PubMed Web of Science ®Google Scholar
• Perkovic V, Ninomiya T, Arima H et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J. Am. Soc. Nephrol.18, 2766–2772 (2007).
   PubMed Web of Science ®Google Scholar
• Guyton AC, Coleman TG, Wilcox CS. Quantitative analysis of the pathophysiology of hypertension. J. Am. Soc. Nephrol.10, 2248–2249 (1999).
   PubMedGoogle Scholar
• Locatelli F, Bommer J, London GM et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatment. Nephrol. Dial. Transplant.16, 459–468 (2001).
   PubMed Web of Science ®Google Scholar
• Bikkina M, Levy D, Evans JC et al. Ventricular mass and risk of stroke in an elderly cohort – the Framingham Heart-Study. JAMA272, 33–36 (1994).
   PubMed Web of Science ®Google Scholar
• Endemann DH, Schiffrin EL. Endothelial dysfunction. J. Am. Soc. Nephrol.15, 1983–1992 (2004).
   PubMed Web of Science ®Google Scholar
• Stehouwer CDA, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J. Am. Soc. Nephrol.17, 2106–2111 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas GN, Lin JW, Lam WW et al. Middle cerebral artery stenosis in Type II diabetic Chinese patients is associated with conventional risk factors but not with polymorphisms of the renin–angiotensin system genes. Cerebrovasc. Dis.16, 217–223 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas GN, Chen XY, Lin JW et al. Middle cerebral artery stenosis increased the risk of vascular disease mortality among Type 2 diabetic patients. Cerebrovasc. Dis.25, 261–267 (2008).
   PubMed Web of Science ®Google Scholar
• Furtner M, Kiechl S, Mair A et al. Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. Eur. Heart J.26, 279–287 (2005).
   PubMed Web of Science ®Google Scholar
• Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int.62, 1524–1538 (2002).
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int.63, 179–185 (2003).
   PubMed Web of Science ®Google Scholar
• Touyz RM, Mercure C, He Y et al. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension45, 530–537 (2005).
   PubMed Web of Science ®Google Scholar
• Daugherty A, Dunn JL, Rateri DL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J. Clin. Invest.94, 437–444 (1994).
   PubMed Web of Science ®Google Scholar
• O’Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension46, 200–204 (2005).
   PubMed Web of Science ®Google Scholar
• Seliger SL, Longstreth WT Jr. Lessons about brain vascular disease from another pulsating organ, the kidney. Stroke39, 5–6 (2008).
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension45, 198–202 (2005).
   PubMed Web of Science ®Google Scholar
• Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with Type 2 diabetes mellitus: a blood pressure-independent effect. Circulation106, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Fassi A, Ilieva AP et al. Preventing microalbuminuria in Type 2 diabetes. N. Engl. J. Med.351, 1941–1951 (2004).
   PubMed Web of Science ®Google Scholar
• Asselbergs FW, Diercks GF, Hillege HL et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation110, 2809–2816 (2004).
   PubMed Web of Science ®Google Scholar
• van de Wal RM, Gansevoort RT, van der Harst P et al. Predictors of angiotensin-converting enzyme inhibitor-induced reduction of urinary albumin excretion in nondiabetic patients. Hypertension48, 870–876 (2006).
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in Type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet376, 419–430 (2010).
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med.358, 2545–2559 (2008).
   PubMed Web of Science ®Google Scholar